Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Eli Lilly is acquiring Merida Biosciences for up to $2.88 billion in cash, aiming to bolster its pipeline in immunity-related and allergic diseases. Merida's lead candidate, MER511, targets antibodies behind autoimmune conditions like Graves' disease and thyroid eye disease. The deal is part of Lilly's broader acquisition push, fueled by blockbuster revenue from its obesity drugs.
Eli Lilly is continuing its dealmaking streak, announcing plans to acquire privately held Merida Biosciences for up to $2.88 billion in cash. The move is squarely aimed at expanding Lilly's pipeline in immunity-related and allergic diseases — a fast-growing therapeutic area with significant unmet need.
Merida's approach centers on selectively targeting antibodies responsible for a range of autoimmune conditions. Its lead drug candidate, MER511, is in early-stage development for disorders including Graves' disease and thyroid eye disease — conditions that currently have limited treatment options.
By the Numbers
Why it matters: Lilly's acquisition signals growing pharmaceutical confidence in antibody-targeting therapies for autoimmune diseases. For patients with conditions like Graves' disease — where treatment options remain limited — this pipeline investment could eventually translate into new, more targeted therapies.
